MM-398: Completed Phase III enrollment

Merrimack completed enrollment of about 405 patients who previously failed treatment with gemcitabine in the open-label, international Phase III NAPOLI-1 trial comparing 120 mg/m 2 IV IMM-398 every 3 ...